Declarations and Acknowledgments
Funding . No funding or sponsorship was received for this study
or publication of this article.
Authorship . All named authors meet the International Committee
of Medical Journal Editors (ICMJE) criteria for authorship for this
article, take responsibility for the integrity of the work as a whole,
and have given their approval for this version to be published.
Disclosures. Ana Borić Bilušić has nothing to disclose. Nada
Božina has nothing to disclose. Zdenka Lalić has nothing to disclose.
Mila Lovrić has nothing to disclose. Sandra Nađ-Škegro has nothing to
disclose. Luka Penezić has nothing to disclose. Karmela Barišić has
nothing to disclose. Vladimir Trkulja has nothing to disclose.
Compliance with Ethics Guidelines. Study was approved by the
Ethics Committee of the University Hospital Center Zagreb (approval No.
8.1-17/242-2 02/21, January 30, 2018). All procedures performed in the
study were in accordance with the 1964 Declaration of Helsinki and its
later amendments. All patients included in the present analysis
underwent standard routine therapeutic drug monitoring in their
post-transplant period. Those meeting inclusion criteria were included
only if they signed an informed consent for genotyping of pharmacogenes
for research purposes.
Data availability . The datasets generated during and/or
analyzed during the current study are available from the corresponding
author on reasonable request.